Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

(2017) Nicolas Mottet et al.   EUROPEAN UROLOGY

The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction

(2017) Florian A. Distler et al.   JOURNAL OF UROLOGY

Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study

(2017) Hashim U Ahmed et al.   LANCET

Re-examining Prostate-specific Antigen (PSA) Density: Defining the Optimal PSA Range and Patients for Using PSA Density to Predict Prostate Cancer Using Extended Template Biopsy

(2017) Joshua S. Jue et al.   UROLOGY

Prostate Cancer Early Detection, Version 1.2014

(2017) Peter R. Carroll et al.   Journal of the National Comprehensive Cancer Network

Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer

(2016) Stacy Loeb et al.   BJU INTERNATIONAL

European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study

(2016) Robert W. Foley et al.   BJU INTERNATIONAL

Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients

(2016) Satoshi Washino et al.   BJU INTERNATIONAL

Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer

(2015) Tobias Nordström et al.   EUROPEAN UROLOGY

Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study

(2015) Richard J. Bryant et al.   JNCI-Journal of the National Cancer Institute

Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study

(2015) Henrik Grönberg et al.   LANCET ONCOLOGY

Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study

(2015) Richard J. Bryant et al.   JNCI-Journal of the National Cancer Institute

Prostate Cancer Mortality in Areas With High and Low Prostate Cancer Incidence

(2014) P. Stattin et al.   JNCI-Journal of the National Cancer Institute

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up

(2014) Fritz H Schröder et al.   LANCET

Variability in MRI vs. ultrasound measures of prostate volume and its impact on treatment recommendations for favorable-risk prostate cancer patients: a case series

(2014) Yonina R Murciano-Goroff et al.   Radiation Oncology

Infectious Complications and Hospital Admissions After Prostate Biopsy in a European Randomized Trial

(2012) Stacy Loeb et al.   EUROPEAN UROLOGY

Prediction of Prostate Cancer Risk: The Role of Prostate Volume and Digital Rectal Examination in the ERSPC Risk Calculators

(2011) Monique J. Roobol et al.   EUROPEAN UROLOGY

Complications After Prostate Biopsy: Data From SEER-Medicare

(2011) Stacy Loeb et al.   JOURNAL OF UROLOGY

Estimating the benefits of PSA screening

(2009) Andrew J. Vickers et al.   Nature Reviews Urology